{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(4)"],"submitter":["Bajpai M"],"pubmed_abstract":["<h4>Importance</h4>No proven treatment is available for severely ill COVID-19. Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation.<h4>Objective</h4>To compare the efficacy of COPLA with standard medical therapy (SMT) alone in severe COVID-19 patients.<h4>Design, setting and participants</h4>A multicentric, open-labelled, phase-III randomised controlled trial conducted at two treatment centres with COPLA collected at the third dedicated centre in North-India, the coordinating centre during trial from June 2020 to December 2020. The study population comprised 400 participants in the ratio of 1:1 in each treatment group.<h4>Intervention</h4>One group received COPLA with SMT (n=200), and another group received SMT only (n=200).<h4>Main outcome measures</h4>Primary o"],"journal":["BMJ open"],"pagination":["e055189"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8987237"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)."],"pmcid":["PMC8987237"],"pubmed_authors":["Jain S","Bharti P","Agarwal R","Agarwal S","Shankar P","Bhardwaj A","Yadav BK","Kumar S","Saluja V","Sarin SK","Maheshwari A","Gupta A","Thomas SS","Dogra V","Narayanan A","Kumar G","Gupta E","Chhabra K","Trehanpati N","Bajpai M","Hussain J","Bihari C","Kale P"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).","description":"<h4>Importance</h4>No proven treatment is available for severely ill COVID-19. Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation.<h4>Objective</h4>To compare the efficacy of COPLA with standard medical therapy (SMT) alone in severe COVID-19 patients.<h4>Design, setting and participants</h4>A multicentric, open-labelled, phase-III randomised controlled trial conducted at two treatment centres with COPLA collected at the third dedicated centre in North-India, the coordinating centre during trial from June 2020 to December 2020. The study population comprised 400 participants in the ratio of 1:1 in each treatment group.<h4>Intervention</h4>One group received COPLA with SMT (n=200), and another group received SMT only (n=200).<h4>Main outcome measures</h4>Primary o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-09T15:35:07.359Z","creation":"2025-04-19T21:47:55.978Z"},"accession":"S-EPMC8987237","cross_references":{"pubmed":["35387813"],"doi":["10.1136/bmjopen-2021-055189"]}}